Personalized immune cell vaccine for colorectal cancer with liver spread
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of colorectal cancer
- You have stage IV colorectal cancer that has spread to the liver
- You have had surgery to remove both the primary tumor and liver tumors, and doctors say you have no remaining evidence of disease
- You are at high risk of the cancer coming back (for example, a high CRS score, successful chemotherapy before surgery, or multiple spots on the lining of the belly that were completely removed)
- Your tumor is pMMR or MSS/MSI-L (a type of tumor that doesn't have certain DNA repair issues)
- You are generally well enough to do your daily activities without needing help (Karnofsky score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new vaccine (YMN-136) for people with colorectal cancer that has spread to the liver and hasn't responded to at least three prior treatments. The goal is to see if the vaccine can help control the cancer.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor), growth factors, and chemotherapy (CapeOX) for people whose colorectal cancer has spread only to the liver. The goal is to see if this combination shrinks the tumors enough to allow surgery to remove them completely.
This trial studies an immune cell treatment made from your own blood cells to treat colorectal cancer that has spread or progressed. You may be eligible if you have stage III–IV disease that can be measured on scans and if standard treatments have not worked or couldn’t be tolerated.
This trial tests a personalized vaccine made from your own tumor cells for advanced colorectal cancer that is mismatch repair proficient (pMMR). It aims to see if the vaccine can help when standard treatments have stopped working.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.